Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Revel RX vs TelePeptide

Revel RX
Graded #47

Higher grade

vs+15
TelePeptide
Graded #273

Lower grade

The verdict

Revel RX takes it — 77.3/100 to 62.3/100.

Revel RX grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Revel RX is a Michigan-based telehealth weight-loss platform offering compounded semaglutide at $89/month and compounded tirzepatide at $155/month — flat-rate at every dose tier.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueRevel RX +52
96
44
Dose & formulationTelePeptide +3
72
75
Clinical oversightTelePeptide +3
84
87
Labs & monitoringTelePeptide +1
53
54
FulfillmentRevel RX +4
81
77
Contract termsRevel RX +35
55
20
Revel RX · left barTelePeptide · right bar

The numbers

MetricRevel RXTelePeptide
WeighScore77.3/10062.3/100
GradeC+C
Scorecard rank#47#273
Semaglutide$89/mo (all doses, compounded)$199/mo (starting dose, annual plan, compounded oral)
Tirzepatide$155/mo (all doses, compounded)$219/mo (starting dose, annual plan, compounded oral)
CoverageCoverage not publishedCoverage not published
Brand-name accessCompounded onlyCompounded only
Oral / sublingualInjection onlyYes
Revel RX

Graded #47 · C+

Strengths

  • Industry-low flat pricing: $89/mo for compounded semaglutide and $155/mo for tirzepatide at every dose
  • LegitScript verified and BBB accredited with an A+ rating — above-average trust signals for a compounded platform
  • Named pharmacy partners: Manifest Pharmacy and Red Rock Home Pharmacy (503A + 503B facilities)
  • Free overnight cold shipping included; no hidden fees or dose-based price increases
  • Clinical review by MD Integrations, an independent medical group, before any prescription is issued

Where it loses points

  • States served are not publicly listed; eligible states requires completing intake to confirm coverage
  • No labs, coaching, or ongoing health support disclosed in any public materials
  • Compounded medications are not FDA-approved (site discloses this)
  • Newer brand with limited public patient reviews or Trustpilot rating
  • Pharmacy partners named but no accreditation details (PCAB, 503B cGMP) published on the site
TelePeptide

Graded #273 · C

Strengths

  • LegitScript-certified (seal ID 49966407); 503A-licensed compounding pharmacies
  • All-inclusive from $169/mo annual — physician eval + Rx + medication + shipping, no hidden fees
  • Broadest formulation menu: injectable sema/tirz, oral dissolvable tablets, sema+naltrexone, microdose combos
  • 24/7 care team messaging + regular check-ins + dosage adjustments included at every tier
  • 48 states + DC coverage (excludes only AK + MS); no insurance required; cancel anytime

Where it loses points

  • Compounded medications are not FDA-approved; no pharmacy partner named publicly
  • Monthly billing costs more — $199/mo (monthly) vs $169/mo (annual) for semaglutide injectable; best rate requires annual prepay
  • Labs not included in any plan
  • Founder disclosed by first name only (Ahmed); no physician names or clinical leadership disclosed publicly
  • Tirzepatide injectable at $249/mo (monthly billing) is above the compounded market average

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard